MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ehjcvp/pvab025

Медицинская библиотека · European heart journal. Cardiovascular pharmacotherapy · 2022

Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS).

Lenders Malte, Nordbeck Peter, Kurschat Christine, Eveslage Maria, Karabul Nesrin, Kaufeld Jessica, Hennermann Julia B, Patten Monica, Cybulla Markus, Müntze Jonas, Üçeyler Nurcan, Liu Dan, Das Anibh M, Sommer Claudia, Pogoda Christian, Reiermann Stefanie, Duning Thomas, Gaedeke Jens, von Cossel Katharina, Blaschke Daniela, Brand Stefan-Martin, Mann W Alexander, Kampmann Christoph, Muschol Nicole, Canaan-Kühl Sima, Brand Eva

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

AIMS: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by a deficiency of the lysosomal enzyme α-galactosidase A (GLA/AGAL), resulting in the lysosomal accumulation of globotriaosylceramide (Gb3). Patients with amenable GLA mutations can be treated with migalastat, an oral pharmacological chaperone increasing endogenous AGAL activity. In this prospective observational multicentre study, safety as well as cardiovascular, renal, and patient-reported outcomes and disease biomarkers were assessed after 12 and 24 months of migalastat treatment under 'real-world' conditions.

METHODS AND

RESULTS

A total of 54 patients (26 females) (33 of these [61.1%] pre-treated with enzyme replacement therapy) with amenable mutations were analysed. Treatment was generally safe and well tolerated. A total of 153 events per 1000 patient-years were detected. Overall left ventricular mass index decreased after 24 months (all: -7.5 ± 17.4 g/m2, P = 0.0118; females: -4.6 ± 9.1 g/m2, P = 0.0554; males: -9.9 ± 22.2 g/m2, P = 0.0699). After 24 months, females and males presented with a moderate yearly loss of estimated glomerular filtration rate (-2.6 and -4.4 mL/min/1.73 m2 per year; P = 0.0317 and P = 0.0028, respectively). FD-specific manifestations/symptoms remained stable (all P > 0.05). A total of 76.9% of females and 50% of males suffered from pain, which has not improved under treatment. FD-specific disease scores (Disease Severity Scoring System and Mainz Severity Score Index) remained stable during treatment. AGAL activities and plasma lyso-Gb3 values remained stable, although some male patients presented with increasing lyso-Gb3 levels over time.

CONCLUSIONS

Treatment with migalastat was generally safe and resulted in most patients in an amelioration of left ventricular mass. However, due to the heterogeneity of FD phenotypes, it is advisable that the treating physician monitors the clinical response regularly.

Для цитирования: Lenders Malte, Nordbeck Peter, Kurschat Christine, Eveslage Maria, Karabul Nesrin, Kaufeld Jessica, Hennermann Julia B, Patten Monica, Cybulla Markus, Müntze Jonas, Üçeyler Nurcan, Liu Dan, Das Anibh M, Sommer Claudia, Pogoda Christian, Reiermann Stefanie, Duning Thomas, Gaedeke Jens, von Cossel Katharina, Blaschke Daniela, Brand Stefan-Martin, Mann W Alexander, Kampmann Christoph, Muschol Nicole, Canaan-Kühl Sima, Brand Eva. Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS).. European heart journal. Cardiovascular pharmacotherapy. 2022. DOI: 10.1093/ehjcvp/pvab025.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.